Evidence map›Paper›PMID 28931903›Full record

ArticleScientific reports2017

Plasmonic Enhancement of Selective Photonic Virus Inactivation.

Mina Nazari, Min Xi, Sarah Lerch, M H Alizadeh, Chelsea Ettinger, Hisashi Akiyama, Christopher Gillespie, Suryaram Gummuluru, Shyamsunder Erramilli, Björn M Reinhard

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Ultrafast-light driven plasmonic inactivation ofJournal of materials chemistry. B · 2026
    Article
  2. Unraveling Plasmon-Enhanced Reactive Oxygen Species Generation through Ultrafast Light.The journal of physical chemistry. C, Nanomaterials and interfaces · 2025
    Article
  3. Review
  4. Review
  5. Article
  6. Plasmonic Enhancement Strategies for Light-Driven Microbe Inactivation.The journal of physical chemistry. C, Nanomaterials and interfaces · 2022
    Article
  7. Review
  8. Nanotechnology: A Potential Weapon to Fight against COVID-19.Particle & particle systems characterization : measurement and description of particle properties and behavior in powders and other disperse systems · 2022
    Review
  9. Article
  10. Article
  11. Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Review
  12. Review
  13. Article
  14. Surface interactions and viability of coronaviruses.Journal of the Royal Society, Interface · 2021
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mina NazariDepartments of Electrical and Computer Engineering, Boston University, Boston, MA, 02215, United States.
Min XiDepartments of Chemistry, Boston University, Boston, MA, 02215, United States.
Sarah LerchDepartments of Chemistry, Boston University, Boston, MA, 02215, United States.
M H AlizadehDepartments of Chemistry, Boston University, Boston, MA, 02215, United States.
Chelsea EttingerDepartment of Microbiology, Boston University School of Medicine, Boston, MA, 02118, United States.
Hisashi AkiyamaDepartment of Microbiology, Boston University School of Medicine, Boston, MA, 02118, United States.
Christopher GillespieNext Generation Bioprocessing, Millipore-Sigma, Bedford, MA, 01730, United States.
Suryaram GummuluruDepartment of Microbiology, Boston University School of Medicine, Boston, MA, 02118, United States.ORCID 0000-0002-8606-8481
Shyamsunder ErramilliDepartments of Physics, Boston University, Boston, MA, 02215, United States. shyam@bu.edu.
Björn M ReinhardDepartments of Chemistry, Boston University, Boston, MA, 02215, United States. bmr@bu.edu.
Boston University · USNext Generation Technology (United States) · US

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7M
Mechanism of cell-associated HIV-1 transmissionR01AI064099 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GUMMULURU, SURYARAM · 2005 to 2020
$5.9M
NIAID NIH HHS P30 AI042853NIAID NIH HHS R01 AI064099
6 · The paper itself

Abstract

Femtosecond (fs) pulsed laser irradiation techniques have attracted interest as a photonic approach for the selective inactivation of virus contaminations in biological samples. Conventional pulsed laser approaches require, however, relatively long irradiation times to achieve a significant inactivation of virus. In this study, we investigate the enhancement of the photonic inactivation of Murine Leukemia Virus (MLV) via 805 nm femtosecond pulses through gold nanorods whose localized surface plasmon resonance overlaps with the excitation laser. We report a plasmonically enhanced virus inactivation, with greater than 3.7-log reduction measured by virus infectivity assays. Reliable virus inactivation was obtained for 10 s laser exposure with incident laser powers ≥0.3 W. Importantly, the fs-pulse induced inactivation was selective to the virus and did not induce any measurable damage to co-incubated antibodies. The loss in viral infection was associated with reduced viral fusion, linking the loss in infectivity with a perturbation of the viral envelope. Based on the observations that physical contact between nanorods and virus particles was not required for viral inactivation and that reactive oxygen species (ROS) did not participate in the detected viral inactivation, a model of virus inactivation based on plasmon enhanced shockwave generation is proposed.

Indexed as

AnimalsCell LineDisinfectionGoldHumansLasersLeukemia Virus, MurineMicrobial ViabilityNanoparticlesOptical PhenomenaRatsVirus InactivationGold

Identifiers

PMID28931903
PMCPMC5607298
OpenAlexW2754843459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.